Doxazosin improves insulin sensitivity in hypertensive patients.
Insulin sensitivity in terms of glucose disposal rate was measured by the hyperinsulinemic/euglycemic clamp technique in 10 hypertensive patients and 7 normotensive control subjects before and after 12 weeks of doxazosin therapy. Supine blood pressure fell significantly, from 150/98 mmHg before treatment to 136/90 mmHg after treatment (systolic P < 0.001/diastolic P < 0.01). The average dose of doxazosin at the end of the study was 3.3 +/- 0.4 mg/day. The glucose disposal rate during the last 30 minutes of the glucose clamp procedure was significantly increased, from 5.8 +/- 0.7 mg/kg/min before to 7.8 +/- 0.7 mg/kg/min after treatment (P < 0.02). Insulin sensitivity was 8.7 +/- 0.4 mg/kg/min in the normotensive subjects, which represented a significant difference when compared with that of the hypertensive subjects before treatment (P < 0.01). Steady-state serum insulin concentrations, as measured during the glucose clamp procedure, were 172 +/- 10.4 microU/ml before and 176 +/- 13.5 microU/ml after doxazosin treatment; these levels were significantly higher than the 137 +/- 7.0 microU/ml reading obtained in the normotensive subjects (P < 0.05). Study results show that hypertensive patients tend to be insulin resistant and that treatment with doxazosin improves insulin sensitivity.
Kageyama
S
S
Department of Internal Medicine (III), Jikei University School of Medicine, Tokyo, Japan.
Yamamoto
J
J
Mimura
A
A
Sakurai
T
T
Ishibashi
K
K
Aihara
K
K
Taniguchi
I
I
Ito
K
K
Isogai
Y
Y
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D017292:Doxazosin / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D015309:Glucose Clamp Technique; D005951:Glucose Tolerance Test; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007333:Insulin Resistance; D008297:Male
D017292:Doxazosin